140 mg
Trade Name
Ibrutinib BOS
Film-coated tablet
Request Type
New Registration
Drug Type
Generic(Multisource) Drug
Approval Date
SFDA Approved Use
Ibrutinib as a single agent or in combination with rituximab or obinutuzumab or venetoclax
is indicated for the treatment of adult patients with previously untreated chronic lymphocyticleukaemia (CLL)
Ibrutinib as a single agent or in combination with bendamustine and rituximab (BR) isindicated for the treatment of adult patients with CLL who have received at least one priortherapy.
Ibrutinib as a single agent is indicated for the treatment of adult patients with Waldenström"smacroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatmentfor patients unsuitable for chemoimmunotherapy.
Ibrutinib in combination with rituximab is indicated for the treatment of adult patients withWM.
is indicated for the treatment of adult patients with previously untreated chronic lymphocyticleukaemia (CLL)
Ibrutinib as a single agent or in combination with bendamustine and rituximab (BR) isindicated for the treatment of adult patients with CLL who have received at least one priortherapy.
Ibrutinib as a single agent is indicated for the treatment of adult patients with Waldenström"smacroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatmentfor patients unsuitable for chemoimmunotherapy.
Ibrutinib in combination with rituximab is indicated for the treatment of adult patients withWM.